S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations

@article{Levine2020SadenosyllmethionineC,
  title={S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations},
  author={M. Taylor Levine and Jin Gao and Senthil Kumaran Satyanarayanan and Sarah Berman and Jack Rogers and David Mischoulon},
  journal={Brain, Behavior, and Immunity},
  year={2020},
  volume={85},
  pages={152-161}
}
View on Elsevier
doi.org
2 Citations

2 Citations

Citation Type

Citation Type

Novel investigational therapeutics for generalized anxiety disorder (GAD)
TLDR
Drug developers should consider implementing trial designs such as sequential parallel comparison design to enhance signal detection, and inclusion of depressive comorbidity may also enhance signal Detection by reducing placebo-responsivity.
Nutrition and immunology in mental health: Precision medicine and integrative approaches to address unmet clinical needs in psychiatric treatments
  • J. Chang, K. Su
  • Psychology, Medicine
    Brain, Behavior, and Immunity
  • 2020

References

SHOWING 1-10 OF 101 REFERENCES
Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence.
TLDR
Overall, SAMe appears to be safe and effective in the treatment of depression, but more research is needed to determine optimal doses and to clarify SAMe's place in the psychopharmacologic armamentarium.
Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder
S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.
TLDR
This review of SAMe in the treatment of major depressive disorder found promising but limited evidence of efficacy and safety to support its use as a monotherapy and as an augmentation for other antidepressants.
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
TLDR
Findings suggest promising treatment effects and potentially overlapping mechanisms of action for CBD in these disorders and indicate the need for further systematic investigation of the viability of CBD as a psychiatric pharmacotherapy.
[Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases].
TLDR
The utility of sulfo-adenosil-L-metionina (SAMe) in the treatment of patients with alcoholic liver disease with a discriminatory function index (Maddrey index), of 32 points or more is confirmed.
[Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases].
TLDR
The utility of sulfo-adenosil-L-metionina (SAMe) in the treatment of patients with alcoholic liver disease with a discriminatory function index (Maddrey index), of 32 points or more is confirmed.
The pharmacology and toxicology of kratom: from traditional herb to drug of abuse
TLDR
There are currently no standard analytical screening techniques for mitragynine and its metabolites following ingestion limiting its detection to more sophisticated techniques like liquid chromatography-mass spectrometry to determine kratom use.
Human Cannabinoid Pharmacokinetics
  • M. Huestis
  • Biology, Chemistry
    Chemistry & biodiversity
  • 2007
TLDR
The cardiovascular and subjective effects of cannabis are blocked by rimonabant, the first CB-1 cannabinoid-receptor antagonist, documenting thatCB-1 receptors mediate these effects of smoked cannabis in humans.
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
TLDR
Preliminary results suggest that SAMe can be an effective, well-tolerated, and safe adjunctive treatment strategy for SRI nonresponders with major depressive disorder and warrant replication.
Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment.
...
1
2
3
4
5
...